Symptom clusters and their impacts on the quality of life of patients with lung cancer receiving immunotherapy: A cross‐sectional study

Abstract

AbstractAimThe objective of this study was to identify symptom clusters in lung cancer patients receiving immunotherapy and explore their impact on the quality of life of patients.BackgroundImmunotherapy is widely used in lung cancer; however, there is little understanding of symptom clusters and their impacts on the quality of life of this population.DesignCross‐sectional study.MethodsThe survey contained the Memorial Symptom Assessment Scale (MSAS), Quality of Life Questionnaire‐Lung Cancer 43 and a self‐designed General Information Evaluation Form. Symptom clusters were identified using exploratory factor analysis (EFA) based on the symptom scores. Spearman correlation analysis was performed to evaluate the associations between each symptom cluster and the patients' quality of life. Multiple linear regression analysis was employed to examine the impact of the symptom clusters on quality of life. This study adhered to the STROBE guidelines.ResultsIn total, 240 participants completed the survey. Five symptom clusters were identified and named according to their characteristics: emotional‐related symptom cluster, lung cancer‐related symptom cluster, physical symptom cluster, skin symptom cluster and neural symptom cluster. All symptom clusters, except for the neural symptom cluster, had a significantly detrimental impact on patient quality of life.ConclusionLung cancer patients undergoing immunotherapy experience a range of symptoms, which can be categorized into five clusters. These symptom clusters have a negative impact on patients' quality of life. Future research should focus on developing interventions for each symptom cluster and their influencing factors.Patient or Public ContributionIn the data collection phase, lung cancer patients undergoing immunotherapy were recruited to participate in the survey.